BOSTON--Master scientist and entrepreneur Robert Langer offered his thoughts on those topics and their relationship to drug delivery to FierceDrugDelivery in his MIT office and later to the field at large at the Partnership Opportunities in Drug Delivery conference in Boston.
Roche's announcement that it will acquire InterMune and its orally delivered drug pirfenidone has pushed the rare lung condition idiopathic pulmonary fibrosis (IPF) into the spotlight. Boehringer Ingelheim also has an oral drug for IPF on the horizon, but a little-known candidate for the condition has the potential to steal the big boys' thunder due to its differentiated delivery mechanism. Read more >>
POPULAR COMMENT THREADS
Scientists in Spain have now developed small particles with the ability to encapsulate and release growth factors when implanted in the brain, ultimately reversing the effects of these diseases by spurring the growth of new, healthy neurons. Read more >>
Talking of breaking internal siloes has become a corporate-speak cliche. But in a speech that could be described as brutally honest, GlaxoSmithKlines' head of drug delivery nevertheless brought the importance of doing so to life during last week's Partnership Opportunities in Drug Delivery conference.
Portal Instruments, a new Boston-based company, secured $11 million for its computerized needle-free drug delivery system via a Series A funding round led by Sanofi, Boston-based VC PBJ Capital and a major medical device company. It became only the third company to receive funding under Sanofi's Sunrise Initiative for early stage companies.
The optimal size of nanoparticles is 50 nanometers, smaller than the 100- to 200-nm ones deployed today, concludes a study by University of Illinois researchers.
Highland Therapeutics, a Toronto-based company with delayed-release technology for ADHD treatment, brought in $25 million to push its lead candidates through mid- and late-stage trials and prepare for commercialization.
Fecal microbiota transplantation enables the reconstitution of gut bacteria, and has been proven effective to treat Clostridium difficile infections of the colon. But, as you can imagine, the nature of the active ingredient presents a tough drug delivery challenge. Luckily, the field is advancing.
From Our Sister Sites
WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
Denmark-based Novo Nordisk said on Friday that it had received a subpoena from a U.S. Attorney who wants some info about its manufacturing operations at a plant in Kalundborg. But the company said it really has no idea why.